The mode of action (MOA) approach reveals interactive effects of environmental pharmaceuticals on Mytilus galloprovincialis.

Aquatic organisms are unintentionally exposed to a large number of pharmaceutical residues in their natural habitats. Ecotoxicological studies have agreed that these compounds are not harmful to aquatic organisms, as their environmental concentrations are typically too low. However, recent reports have shown biological effects at such low concentrations when biological endpoints related to the therapeutic effects are assessed. Therefore, conservation of molecular targets is now addressed as a key aspect for the development of more efficient test strategies for pharmaceutical environmental risk assessment, providing the rationale for the mode of action (MOA) approach. In the present study the MOA approach was used to investigate the interactive effects of fluoxetine (FX) and propranolol (PROP) on the Mediterranean mussels (Mytilus galloprovincialis). Indeed, organisms in the environment are exposed to pharmaceutical mixtures throughout their lifetime, and particular combinations may be of concern. The antidepressant FX increases serotonin (5-HT) levels in the synaptic cleft by inhibiting 5-HT reuptake. PROP, a prototypical β-adrenoceptor antagonist, also blocks 5-HT1 receptors, which are negatively coupled to cAMP-mediated signaling. Cell signaling alterations potentially triggered by 5-HT1 receptor occupation were therefore assessed after a 7-day mussel exposure to FX or PROP, alone or in combination, each at 0.3 ng/L concentration. FX decreased cAMP levels and PKA activities in digestive gland and mantle/gonads, in agreement with an increased occupation of 5-HT1 receptors. PROP caused a decrease in cAMP levels and PKA activities in digestive gland and an increase in cAMP levels in mantle/gonads, consistent with a differential expression of adrenergic and 5-HT receptors in the two tissues. Co-exposure to FX and PROP provides significant indications for antagonistic effects of the pharmaceuticals, consistent with a direct (PROP) and indirect (FX) action on the same molecular target. Interestingly, FX induced over-expression of a 5-HT1 gene product, and PROP counteracted such increase when the mixture was administered, while having per se no effect. Finally, mRNA expression of the ABCB gene encoding the MXR-related transporter P-glycoprotein was reduced by both pharmaceuticals in the digestive gland, while decreased by FX, increased by PROP, and not affected by the mixture in mantle/gonads. Since transcription of this gene product is under cAMP/PKA modulation, the impairment of regulatory pathways triggered by low concentrations of pharmaceuticals have the potential to affect the ability of animals to elaborate strategies of defense or adaptation toward further stress factors. In this specific case, the pharmaceutical mixture limits the detrimental effects of the single compounds.

[1]  A. Tierney Structure and function of invertebrate 5-HT receptors: a review. , 2001, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

[2]  J. Rotchell,et al.  Reference gene selection for qPCR in mussel, Mytilus edulis, during gametogenesis and exogenous estrogen exposure , 2012, Environmental Science and Pollution Research.

[3]  T. Newton,et al.  Environmental occurrence and reproductive effects of the pharmaceutical fluoxetine in native freshwater mussels , 2010, Environmental toxicology and chemistry.

[4]  E. Fabbri,et al.  Effects of environmental concentrations of the antiepilectic drug carbamazepine on biomarkers and cAMP-mediated cell signaling in the mussel Mytilus galloprovincialis. , 2009, Aquatic toxicology.

[5]  D. Dietrich,et al.  Physiological Endpoints for Potential SSRI Interactions in Fish , 2008, Critical reviews in toxicology.

[6]  Stewart F Owen,et al.  Uptake of propranolol, a cardiovascular pharmaceutical, from water into fish plasma and its effects on growth and organ biometry. , 2009, Aquatic toxicology.

[7]  J. Rotchell,et al.  Estrogens disrupt serotonin receptor and cyclooxygenase mRNA expression in the gonads of mussels (Mytilus edulis). , 2010, Aquatic toxicology.

[8]  Brett J. Vanderford,et al.  Analysis of pharmaceuticals in water by isotope dilution liquid chromatography/tandem mass spectrometry. , 2006, Environmental science & technology.

[9]  Flavio Mignone,et al.  Gene Expression Rhythms in the Mussel Mytilus galloprovincialis (Lam.) across an Annual Cycle , 2011, PloS one.

[10]  E. Fabbri,et al.  Exposure of mussels to a polluted environment: insights into the stress syndrome development. , 2010, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[11]  C. Delerue-Matos,et al.  Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment. , 2010, Journal of hazardous materials.

[12]  J. Rotchell,et al.  Identification of Reproduction-Specific Genes Associated with Maturation and Estrogen Exposure in a Marine Bivalve Mytilus edulis , 2011, PloS one.

[13]  J. Sekizawa,et al.  The effects of pH on fluoxetine in Japanese medaka (Oryzias latipes): acute toxicity in fish larvae and bioaccumulation in juvenile fish. , 2008, Chemosphere.

[14]  L. Kumblad,et al.  Physiological effects of diclofenac, ibuprofen and propranolol on Baltic Sea blue mussels. , 2010, Aquatic toxicology.

[15]  K. Fent,et al.  Highly active human pharmaceuticals in aquatic systems: A concept for their identification based on their mode of action. , 2010, Aquatic toxicology.

[16]  Colin R. Janssen,et al.  Validation and application of an LC-MS/MS method for the simultaneous quantification of 13 pharmaceuticals in seawater , 2010, Analytical and bioanalytical chemistry.

[17]  Alistair B A Boxall,et al.  Veterinary medicines and the environment. , 2010, Handbook of experimental pharmacology.

[18]  C. Gagnon,et al.  Neuroendocrine disruption and health effects in Elliptio complanata mussels exposed to aeration lagoons for wastewater treatment. , 2007, Chemosphere.

[19]  E. Fabbri,et al.  Cyclic-AMP Mediated Regulation of ABCB mRNA Expression in Mussel Haemocytes , 2013, PloS one.

[20]  P. Fong,et al.  Putative serotonin reuptake inhibitor-induced spawning and parturition in freshwater bivalves is inhibited by mammalian 5-HT2 receptor antagonists. , 2003, Journal of experimental zoology. Part A, Comparative experimental biology.

[21]  K. Fent,et al.  Ecotoxicology of human pharmaceuticals. , 2006, Aquatic toxicology.

[22]  T. Vasskog,et al.  Occurrence of selective serotonin reuptake inhibitors in sewage and receiving waters at Spitsbergen and in Norway. , 2008, Journal of chromatography. A.

[23]  Jacob K Stanley,et al.  Aquatic ecotoxicology of fluoxetine. , 2003, Toxicology letters.

[24]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[25]  A. Viarengo,et al.  Quantitative PCR analysis of two molluscan metallothionein genes unveils differential expression and regulation. , 2005, Gene.

[26]  K. Thomasb,et al.  Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom , 2004 .

[27]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[28]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[29]  H. Jang,et al.  Occurrence of Pharmaceutical and Personal Care Products (PPCPs) in Surface Water from Mankyung River, South Korea , 2009 .

[30]  A. Viarengo,et al.  The Organophosphate Chlorpyrifos Interferes with the Responses to 17β-Estradiol in the Digestive Gland of the Marine Mussel Mytilus galloprovincialis , 2011, PloS one.

[31]  J. Parrott,et al.  Environmental risk assessment for the serotonin re‐uptake inhibitor fluoxetine: Case study using the European risk assessment framework , 2010, Integrated environmental assessment and management.

[32]  John Struger,et al.  Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada , 2003, Environmental toxicology and chemistry.

[33]  Colin R. Janssen,et al.  Rapid quantification of pharmaceuticals and pesticides in passive samplers using ultra high performance liquid chromatography coupled to high resolution mass spectrometry. , 2011, Journal of chromatography. A.

[34]  D. Barceló,et al.  Development of a multi-residue analytical methodology based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for screening and trace level determination of pharmaceuticals in surface and wastewaters. , 2006, Talanta.

[35]  M. Cleuvers Initial risk assessment for three β-blockers found in the aquatic environment , 2005 .

[36]  Gerald T Ankley,et al.  Repeating history: pharmaceuticals in the environment. , 2007, Environmental science & technology.

[37]  C. Hiemke,et al.  Pharmacokinetics of selective serotonin reuptake inhibitors. , 2000, Pharmacology & therapeutics.

[38]  E. Fabbri,et al.  Cyclic AMP signaling in bivalve molluscs: an overview. , 2010, Journal of experimental zoology. Part A, Ecological genetics and physiology.

[39]  J. Hellou,et al.  Up-regulation of hepatic ABCC2, ABCG2, CYP1A1 and GST in multixenobiotic-resistant killifish (Fundulus heteroclitus) from the Sydney Tar Ponds, Nova Scotia, Canada. , 2009, Marine environmental research.

[40]  Jürg Oliver Straub,et al.  Recommendations on the environmental risk assessment of pharmaceuticals: Effect characterization , 2010, Integrated environmental assessment and management.

[41]  Bard,et al.  Multixenobiotic resistance as a cellular defense mechanism in aquatic organisms. , 2000, Aquatic toxicology.

[42]  Erik Kristiansson,et al.  Evolutionary conservation of human drug targets in organisms used for environmental risk assessments. , 2008, Environmental science & technology.

[43]  M. Weir β-Blockers in the Treatment of Hypertension: Are There Clinically Relevant Differences? , 2009, Postgraduate medicine.

[44]  T. Heberer Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. , 2002, Toxicology letters.

[45]  E. Thurman,et al.  Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. , 2002, Environmental science & technology.

[46]  E. Thurman,et al.  Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. , 2002 .

[47]  N. Ichikawa,et al.  Acute toxicity of pharmaceutical and personal care products on freshwater crustacean (Thamnocephalus platyurus) and fish (Oryzias latipes). , 2009, The Journal of toxicological sciences.

[48]  E. Fabbri,et al.  The β-blocker propranolol affects cAMP-dependent signaling and induces the stress response in Mediterranean mussels, Mytilus galloprovincialis. , 2011, Aquatic toxicology.

[49]  M. Dufau,et al.  Serotonergic inhibition of rat Leydig cell function by propranolol. , 1993, Endocrinology.

[50]  Patrick H. Davies,et al.  Toxicology and Chemistry of Metals in Urban Runoff , 1986 .

[51]  M. Cleuvers Initial risk assessment for three beta-blockers found in the aquatic environment. , 2005, Chemosphere.

[52]  M. Wood,et al.  Stereoselective blockade of central [3H]5‐hydroxytryptamine binding to multiple sites (5‐HT1A, 5‐HT1B and 5‐HT1C) by mianserin and propranolol , 1987, The Journal of pharmacy and pharmacology.

[53]  K. Thomas,et al.  The occurrence of selected human pharmaceutical compounds in UK estuaries. , 2004, Marine pollution bulletin.

[54]  A. Viarengo,et al.  Interactive effects of nickel and chlorpyrifos on Mediterranean mussel cAMP-mediated cell signaling and MXR-related gene expressions. , 2011, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[55]  Richard Murray-Smith,et al.  Comparative aquatic toxicity of propranolol and its photodegraded mixtures: Algae and rotifer screening , 2009, Environmental toxicology and chemistry.

[56]  Daniel Hoyer,et al.  Molecular biology of 5-HT receptors , 2008, Behavioural Brain Research.

[57]  C. DeVane Metabolism and Pharmacokinetics of Selective Serotonin Reuptake Inhibitors , 1999, Cellular and Molecular Neurobiology.

[58]  D. Larsson,et al.  Effluent from drug manufactures contains extremely high levels of pharmaceuticals. , 2007, Journal of hazardous materials.

[59]  I. Martin,et al.  Molecular biology of 5-HT receptors , 1994, Neuropharmacology.